Skip to main content

Day: May 27, 2022

Medallion Resources Announces Results of Annual General and Special Meeting of Shareholders

VANCOUVER, British Columbia, May 27, 2022 (GLOBE NEWSWIRE) — Medallion Resources Ltd. (TSX-V: MDL; OTCQB: MLLOF; Frankfurt: MRDN – “Medallion” or the “Company”) is pleased to announce that shareholders have approved all resolutions put forth at the Annual General and Special Meeting of Shareholders (the “Shareholders’ Meeting”) held in Vancouver, BC, on May 27, 2022. In the annual meeting, 34.86% of the eligible shares were represented and all motions put forward by the Company were passed. The number of directors of the Company was fixed at six and Mark Saxon, Rod McKeen, David Shaw, Andrew Morden, Gabriel Alonso-Mendoza and Kurt Forrester were elected as directors of the Company to hold office until the next annual general meeting.  Davidson LLP was re-appointed as auditors of the company and the board is authorized to fix the...

Continue reading

HEMPSANA Announces Q1 2022 Financial Results

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES. TORONTO, May 27, 2022 (GLOBE NEWSWIRE) — Hempsana Holdings Ltd. (the “Company” or “Hempsana”) today announced first quarter financial results for the three-month period ended March 31, 2022. Randy Ko, Hempsana’s CEO commented: “During the first quarter of 2022 we extended our cannabinoid portfolio with the commercialization of cannabigerol (“CBG”) with plans to commercialize cannabinol (“CBN”) in Q2. We also advanced our contract manufacturing business by signing commercial agreements with several leading brands. With our first OCS product launch of the UfeelU branded CBG cannabis extract expected in May, we are seeing growing interest from brands looking...

Continue reading

FDA approves Novartis Kymriah® CAR-T cell therapy for adult patients with relapsed or refractory follicular lymphoma

68% of patients receiving Kymriah in the ELARA trial experienced complete response, with an 86% overall response rate, along with a remarkable safety profile1Sustained clinical benefit from Kymriah treatment demonstrated – of patients who achieved a complete response, 85% were still in response at 12 months1Kymriah can be administered in the outpatient setting, offering increased flexibility and potentially reducing the burden of therapy for patients and their care teams1,2Kymriah is now FDA approved in three indications and remains the only CAR-T cell therapy approved in both adult and pediatric settings1Basel, May 28, 2022 — Novartis today announced the US Food and Drug Administration (FDA) has granted accelerated approval for Kymriah® (tisagenlecleucel) for the treatment of adult patients with relapsed or refractory (r/r)...

Continue reading

Baden Resources Update

VANCOUVER, British Columbia, May 27, 2022 (GLOBE NEWSWIRE) — Baden Resources Inc. (“Baden” or the “Company”) (CSE:”BDN”) completed exploration in late 2021 on the Midway mining claims property located in southeastern BC, held under option with the claims owner. Baden has completed its firm commitments under the subject option agreement, which included analysis of samples obtained, and has now concluded that the results do not warrant any further expenditure. Baden accordingly will not be proceeding any further with the Midway property and the option and has terminated the option agreement with the owner. The Company is a mineral exploration company focused on the acquisition, exploration and development of mineral properties in Canada and the USA. On Behalf of the Company Howard Milne, Chief Executive Officer For further information,...

Continue reading

AM Resources Provides Update on Private Placement and MCTO

MONTREAL, May 27, 2022 (GLOBE NEWSWIRE) — AM Resources Corporation (“AM” or the “Corporation”) (TSXV: AMR) (Frankfurt: 76A) is providing investors with an update on its non-brokered private placement (the “Private Placement”) of up to 40,000,000 units (each a “Unit”) at a price of $0.05 per Unit, for gross proceeds of up to $2,000,000. As previously announced, the Corporation has completed a first and a second tranche for aggregate gross proceeds of $1,315,500, consisting of the issuance of 26,310,000 Units. Each Unit is comprised of one common share of the Corporation and one-half of one warrant. Each warrant entitles the holder to acquire one common share of the Corporation at a price of $0.075 for a period of 24 months following the closing of the Private Placement. The Corporation expects to complete the Private Placement early...

Continue reading

Akerna Announces Corporate Restructuring

Consolidation, Headcount, and Reductions Expected to Yield Material Annualized Cost Savings, effective July 1, 2022 DENVER, May 27, 2022 (GLOBE NEWSWIRE) — Akerna Corp. (Nasdaq: KERN) (“Akerna”), a leading enterprise software company and developer of one of the most comprehensive technology infrastructures, ecosystems, and compliance engines powering the global cannabis industry, today announced that the Company is implementing a plan to reduce its workforce and operating costs in order to focus its resources, accelerate its path to profitability, and create stakeholder value. “Our sales performance in 2022 has thus far met our expectations. We believe we are showing signs of progress with revenue now at a run rate of $27m at last filing,” commented Jessica Billingsley, Akerna’s Chief Executive Officer. “While we believe we can...

Continue reading

CF Energy Announces Financial Results For The Three-month period ended March 31, 2022

TORONTO, May 27, 2022 (GLOBE NEWSWIRE) — CF Energy Corp., (TSX-V: CFY) (“CF Energy” or the “Company”, together with its subsidiaries, the “Group”), an energy provider in the People’s Republic of China (the ”PRC” or “China”), announces that the Company has filed its unaudited condensed interim consolidated financial results for the three-month period ended March 31, 2022. Results for the three-month period ended March 31, 2022 (“Q1 2022”)In millions Q1 2022 Q1 2021 Change   % Q1 2022 Q1 2021 Change   %(except for % figures) RMB RMB RMB     CAD CAD CAD    Continuing Operations                    Revenue 95.4 81.2 14.2   17% 19.0 15.9 3.1   17%Gross Profit 37.3 33.6 3.7   11% 7.5 6.6 0.9   11%Gross Profit Margin 39.2% 41.4% -2.2%     39.2% 41.4% -2.2%    Net Profit 11.3 3.0 8.3   279% 2.3 0.6 1.7   279%Adjusted...

Continue reading

Allarity Therapeutics Reports First Quarter 2022 Financial Results

Cambridge, MA U.S.A. (May 27, 2022) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion diagnostics for personalized cancer care, today reported financial results for the first quarter ended March 31, 2022. First Quarter Financial Results Balance Sheet: As of March 31, 2022, Allarity’s cash was $14.5 million, as compared to $19.6 million as of December 31, 2021. R&D Expenses: Research and Development (R&D) expenses were $1.3 million for the three months ended March 31, 2022, compared to $1.3 million for the quarter ended March 31, 2021. Impairment of Intangible Assets: Impairment of Intangible Assets was $14.0 million for the three months ended March 31, 2022, compared to nil for the quarter ended...

Continue reading

Leonovus Inc. Files Q1 2022 Financial Results and Business Update

OTTAWA, May 27, 2022 (GLOBE NEWSWIRE) — Leonovus Inc., (“Leonovus”) (TSXV: LTV) announces the filing of its unaudited Interim Financial Statements and Management Discussion and Analysis (“MD&A“) for the quarter ended March 31, 2022. The MD&A provides a comprehensive discussion of Leonovus’ financial position, and the results of operations are available on SEDAR at www.sedar.com. Amounts are in Canadian dollars. On April 28, 2022, the Company launched Torozo, its software as a service (“SaaS”) (www.torozo.com) to the public marketplace. Torozo is a hyper-secure file sharing, file transfer and file storage service. The initial target markets are legal firms and financial users, where users need a more secure document sharing and transfer method than email or current less secure...

Continue reading

Wellbeing Digital Sciences Announces Resignation of Chief Financial Officer

VANCOUVER, British Columbia, May 27, 2022 (GLOBE NEWSWIRE) — Wellbeing Digital Sciences Inc. (“Wellbeing” or the “Company”) (NEO: MEDI) (OTC: KONEF) (FRA: SQ2), an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including psychedelic medicine and digital therapeutics as supported by clinical research, announces the resignation of its Chief Financial Officer, Joseph Ramelli. The Board of Directors thanks Mr. Ramelli for his contributions to Wellbeing since accepting the role in late 2021. The Company expects to announce the appointment of a new Chief Financial Officer in the near future. ABOUT WELLBEING DIGITAL SCIENCES Wellbeing Digital Sciences Inc. is an evidence-based mental healthcare company focused on the development and implementation of innovative...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.